Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.57 |
| ▸ | JAK1 | P23458 | 18/20 | 0.57 |
| ▸ | TYK2 | P29597 | 7/20 | 0.57 |
| ▸ | JAK3 | P52333 | 7/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893893 | 0.94 | JAK2 (0.62) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL20560479 | 0.87 | JAK2 (0.58) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL30273461 | 0.87 | JAK2 (0.58) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL20560911 | 0.86 | JAK2 (0.62) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL30273439 | 0.86 | JAK2 (0.62) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL18893911 | 0.86 | JAK2 (0.74) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL18894024 | 0.86 | IRAK4 (0.52) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL31039847 | 0.86 | IRAK4 (0.52) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL22801365 | 0.86 | IRAK4 (0.64) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL18893912 | 0.85 | IRAK4 (0.54) | JAK2JAK1TYK2JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630766-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-11-29 | — | — | WO | disclosed |